Striatal development involves a switch in gene expression networks, Followed by a myelination event: Implications for neuropsychiatric disease

Synapse

Volumn 67, Issue 4, 2013, Pages 179-188

  Novak, Gabriela ^a,b   Fan, Theresa ^a   O'dowd, Brian F ^a,b   George, Susan R ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dopamine; Gene expression; Medium spiny neurons; Neurodevelopment; Schizophrenia; Striatum

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR;

ADULTHOOD; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DEVELOPMENTAL GENE; FRONTAL CORTEX; GENE FUNCTION; GENE REGULATORY NETWORK; GENE SWITCHING; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GROUPS BY AGE; MATURATION; MENTAL DISEASE; MYELINATION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; PRIORITY JOURNAL; RAPGEF5 GENE; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLICING DEFECT; SUBTRACTIVE HYBRIDIZATION;

ANIMALS; GABAERGIC NEURONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE REGULATORY NETWORKS; MODELS, ANIMAL; MYELIN SHEATH; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84873995633     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21628     Document Type: Article

References (79)

1. Alexander GE, DeLong MR, Strick PL. 1986. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381.
2. Ang SL. 2006. Transcriptional control of midbrain dopaminergic neuron development. Development 133: 3499-3506.
3. Araki KY, Sims JR, Bhide PG. 2007. Dopamine receptor mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and postnatal development. Brain Res 1156: 31-45.
4. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, Winiger E, Breier A, Shekhar A, Amdur R, Koller D, Nurnberger JI, Corvin A, Geyer M, Tsuang MT, Salomon D, Schork NJ, Fanous AH, O'Donovan MC, Niculescu AB. 2012. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 17: 887-905.
5. Bao Y, Ibram G, Blaner WS, Quesenberry CP, Shen L, McKeague IW, Schaefer CA, Susser ES, Brown AS. 2012. Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophrenia Res 137: 159-165.
6. Bartzokis G, Lu PH, Tishler TA, Fong SM, Oluwadara B, Finn JP, Huang D, Bordelon Y, Mintz J, Perlman S. 2007. Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochem Res 32: 1655-1664.
7. Ben-Ari Y, Khalilov I, Represa A, Gozlan H. 2004. Interneurons set the tune of developing networks. Trends Neurosci 27: 422-427.
8. Bithell A, Alberta J, Hornby F, Stiles CD, Williams BP. 2003. Expression of the guanine nucleotide exchange factor, mr-gef, is regulated during the differentiation of specific subsets of telencephalic neurons. Brain Res Dev Brain Res 146: 107-118.
9. Bodnar RJ. 2007. Endogenous opiates and behavior: 2006. Peptides 28: 2435-2513.
10. Boksa P, El-Khodor BF. 2003. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev 27: 91-101.
11. Bolam JP, Hanley JJ, Booth PA, Bevan MD. 2000. Synaptic organisation of the basal ganglia. J Anat 196(Pt 4): 527-542.
12. Brown AS, Patterson PH. 2011. Maternal infection and schizophrenia: Implications for prevention. Schizophrenia Bull 37: 284-290.
13. Buxbaum JD. 2004. A role for calsenilin and related proteins in multiple aspects of neuronal function. Biochem Biophys Res Commun 322: 1140-1144.
14. Clancy B, Darlington RB, Finlay BL. 2001. Translating developmental time across mammalian species. Neuroscience 105: 7-17.
15. Connor JR, Fine RE. 1987. Development of transferrin-positive oligodendrocytes in the rat central nervous system. J Neurosci Res 17: 51-59.
16. Crandall JE, McCarthy DM, Araki KY, Sims JR, Ren JQ, Bhide PG. 2007. Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J Neurosci 27: 3813-3822.
17. Crittenden JR, Graybiel AM. 2011. Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front Neuroanat 5: 59.
18. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60(5): 443-456.
19. Deng YP, Xie JP, Wang HB, Lei WL, Chen Q, Reiner A. 2007. Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats. J Chem Neuroanat 33: 167-192.
20. Dujardin K, Laurent B. 2003. Dysfunction of the human memory systems: Role of the dopaminergic transmission. Current opinion in neurology 16(Suppl 2): S11-S16.
21. Dusek P, Jankovic J, Le W. 2012. Iron dysregulation in movement disorders. Neurobiol Dis 46: 1-18.
22. Egan MF, Weinberger DR. 1997. Neurobiology of schizophrenia. Curr Opin Neurobiol 7: 701-707.
23. Escobar Cabrera OE, Bongarzone ER, Soto EF, Pasquini JM. 1994. Single intracerebral injection of apotransferrin in young rats induces increased myelination. Developmental Neurosci 16: 248-254.
24. Fatemi SH, Reutiman TJ, Folsom TD, Huang H, Oishi K, Mori S, Smee DF, Pearce DA, Winter C, Sohr R, Juckel G. 2008. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: Implications for genesis of neurodevelopmental disorders. Schizophrenia Res 99: 56-70.
25. Felsky D, Voineskos AN, Lerch JP, Nazeri A, Shaikh SA, Rajji TK, Mulsant BH, Kennedy JL. 2012. Myelin-associated glycoprotein gene and brain morphometry in schizophrenia. Front Psychiatry/Front Res Found 3: 40.
26. Fishell G, van der Kooy D. 1987. Pattern formation in the striatum: developmental changes in the distribution of striatonigral neurons. J Neurosci 7: 1969-1978.
27. Fishell G, van der Kooy D. 1989. Pattern formation in the striatum: Developmental changes in the distribution of striatonigral projections. Brain Res Dev Brain Res 45: 239-255.
28. Fredriksson A, Archer T, Alm H, Gordh T, Eriksson P. 2004. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav Brain Res 153: 367-376.
29. Furuta T, Mori T, Lee T, Kaneko T. 2000. Third group of neostriatofugal neurons: Neurokinin B-producing neurons that send axons predominantly to the substantia innominata. J Comp Neurol 426: 279-296.
30. Gerfen CR. 1992. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15: 285-320.
31. Gerfen CR, Young WS, III. 1988. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res 460: 161-167.
32. Goetz T, Arslan A, Wisden W, Wulff P. 2007. GABA(A) receptors: Structure and function in the basal ganglia. Prog Brain Res 160: 21-41.
33. Greenstein R, Novak G, Seeman P. 2007. Amphetamine sensitization elevates CaMKIIbeta mRNA. Synapse 61: 827-834.
34. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98: 4746-4751.
35. Hansen HH, Briem T, Dzietko M, Sifringer M, Voss A, Rzeski W, Zdzisinska B, Thor F, Heumann R, Stepulak A, Bittigau P, Ikonomidou C. 2004. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol Dis 16: 440-453.
36. Harkany T, Mackie K, Doherty P. 2008. Wiring and firing neuronal networks: Endocannabinoids take center stage. Curr Opin Neurobiol 18: 338-345.
37. 2+ currents and excitability via a novel PLCβ1-IP3-calcineurin-signaling cascade. J Neurosci 20: 8987-8995.
38. Hwang CK, D'souza UM, Eisch AJ, Yajima S, Lammers CH, Yang Y, Lee SH, Kim YM, Nestler EJ, Mouradian MM. 2001. Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor. Proc Natl Acad Sci U S A 98: 7558-7563.
39. Jocoy EL, Andre VM, Cummings DM, Rao SP, Wu N, Ramsey AJ, Caron MG, Cepeda C, Levine MS. 2011. Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-D-aspartate currents by dopamine D1 receptor activation in striatum. Front Syst Neurosci 5: 28.
40. Johns TG, Bernard CC. 1999. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 72: 1-9.
41. Katsel P, Davis KL, Haroutunian V. 2005. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study. Schizophrenia Res 79: 157-173.
42. Keshavan MS, Murray R. 1997. Neurodevelopment & adult psychopathology, Vol. 16. Cambridge, New York: Cambridge University Press. 282p.
43. Kreitzer AC, Malenka RC. 2008. Striatal plasticity and basal ganglia circuit function. Neuron 60: 543-554.
44. Lau WK, Lui PW, Wong CK, Chan YS, Yung KK. 2003. Differential expression of N-methyl-D-aspartate receptor subunit messenger ribonucleic acids and immunoreactivity in the rat neostriatum during postnatal development. Neurochem Int 43: 47-65.
45. Laviolette SR, Grace AA. 2006. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol Life Sci: CMLS 63: 1597-1613.
46. Lee SH, Jang MK, Lee OH, Kim OS, Kim YM, Yajima S, Lee YC, Mouradian MM. 2008. Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene. Mol Cell Endocrinol 289: 23-28.
47. Leitner DF, Connor JR. 2012. Functional roles of transferrin in the brain. Biochim Biophys Acta 1820: 393-402.
48. Lobo MK, Karsten SL, Gray M, Geschwind DH, Yang XW. 2006. FACS-array profiling of striatal projection neuron subtypes in juvenile and adult mouse brains. Nat Neurosci 9: 443-452.
49. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, Falkai P, Schmitt A, Turck CW. 2010. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44: 1176-1189.
50. Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E, Herve D, Girault JA. 2009. Striatal medium-sized spiny neurons: Identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PloS one 4(3): e4770.
51. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH. 2007. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophrenia Res 90: 15-27.
52. Mednick SA, Huttunen MO, Machon RA. 1994. Prenatal influenza infections and adult schizophrenia. Schizophrenia Bull 20: 263-267.
53. Mednick SA, Machon RA, Huttunen MO, Bonett D. 1988. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45: 189-192.
54. Meyer U. 2011. Developmental neuroinflammation and schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry, Available online 15 November 2011, In Press.
55. Meyer U, Weiner I, McAlonan GM, Feldon J. 2011. The neuropathological contribution of prenatal inflammation to schizophrenia. Expert Rev Neurotherapeutics 11: 29-32.
56. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. 2002. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5: 267-271.
57. Novak G, Seeman P. 2010. Hyperactive mice show elevated D2High receptors, a model for schizophrenia: Calcium/calmodulin-dependent kinase II alpha knockouts. Synapse 64:794-800.
58. Novak G, Tallerico T. 2006. Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3′-UTR. Brain Res 1120: 161-171.
59. Novak G, Seeman P, Tallerico T. 2006. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse 59: 61-68.
60. Odeon MM, Salatino AE, Rodriguez CB, Scolari MJ, Acosta GB. 2010. The response to postnatal stress: amino acids transporters and PKC activity. Neurochem Res 35: 967-975.
61. Palomo T, Kostrzewa RM, Archer T, Beninger RJ. 2002. Neurodevelopmental liabilities in schizophrenia and affective disorders. Neurotox Res 4: 397-408.
62. Popot JL, Pham Dinh D, Dautigny A. 1991. Major myelin proteolipid: The 4-alpha-helix topology. J Membr Biol 123: 278.
63. Preston Z, Richardson PJ, Pinnock RD, Lee K. 2000. NK-3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [(3)H] gamma-aminobutyric acid release. Neurosci Lett 284: 89-92.
64. Readhead C, Schneider A, Griffiths I, Nave KA. 1994. Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 12: 583-595.
65. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. 1991. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J Neurochem 57: 1062-1067.
66. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. 2007. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83: 277-292.
67. Schwarzer C. 2009. 30 years of dynorphins-New insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123: 353-370.
68. Seeman P. 2011. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17: 118-132.
69. Sibley DR. 1995. Molecular biology of dopamine receptors. In: Ariano MA, Surmeier DJ, editors. Molecular and cellular mechanisms of neostriatal function. New York, Austin: Springer, R.G. Landes. p 255-272.
70. Simpson EH, Kellendonk C, Kandel E. 2010. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65: 585-596.
71. Sokolov BP. 2007. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 10: 547-555.
72. Tamura S, Morikawa Y, Iwanishi H, Hisaoka T, Senba E. 2004. Foxp1 gene expression in projection neurons of the mouse striatum. Neuroscience 124: 261-267.
73. Tatar CL, Appikatla S, Bessert DA, Paintlia AS, Singh I, Skoff RP. 2010. Increased Plp1 gene expression leads to massive microglial cell activation and inflammation throughout the brain. ASN Neuro 2: e00043.
74. Tepper JM, Bolam JP. 2004. Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 14: 685-692.
75. Teramitsu I, Kudo LC, London SE, Geschwind DH, White SA. 2004. Parallel FoxP1 and FoxP2 expression in songbird and human brain predicts functional interaction. J Neurosci 24: 3152-3163.
76. Thomas EA. 2006. Striatal specificity of gene expression dysregulation in Huntington's disease. J Neurosci Res 84: 1151-1164.
77. Watanabe Y, Someya T, Nawa H. 2010. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin Neurosci 64: 217-230.
78. Welham J, Isohanni M, Jones P, McGrath J. 2009. The antecedents of schizophrenia: A review of birth cohort studies. Schizophrenia Bull 35: 603-623.
79. Zhang X, Andren PE, Chergui K, Svenningsson P. 2008. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology 54: 1143-1152.